Skip to content

Effects of Chicken Protein Hydrolysate Supplementation With and Without Concurrent Training on Arterial Stiffness and Blood Pressure in Adults With Hypertension

Effects of Chicken Protein Hydrolysate Supplementation With and Without Concurrent Training on Arterial Stiffness and Blood Pressure in Adults With Hypertension

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20251210008
Enrollment
36
Registered
2025-12-10
Start date
2021-01-10
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension blood pressure, concurrent training, arterial stiffness, protein supplementation, inflammation

Interventions

Placebo crackers (isocaloric
no chicken protein hydrolysate), no concurrent training,Chicken protein hydrolysate crackers (20 g protein/day), no concurrent training,Chicken protein hydrolysate crackers (20 g protein/day) with sup
Placebo control group,Chicken protein hydrolysate crackers group,Combined chicken protein hydrolysate crackers and concurrent training

Sponsors

Kamphaeng Saen Campus Targeted Research Grant, Kasetsart University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 59 Years

Inclusion criteria

Inclusion criteria: 1.Adults with hypertension (SBP greater than or equal to130 mmHg or DBP greater than or equal to80 mmHg ) 2.Age 35-59 years 3.Body mass index greater than or equal to 23 kg per m2 4.Sedentary lifestyle 5.Stable antihypertensive medication use (if any) for greater than or equal to 3 months 6.No participation in supervised exercise or nutrition programs in the preceding 3 months 7.Able and willing to comply with study procedures, supplementation, and exercise sessions 8.Provided written informed consent

Exclusion criteria

Exclusion criteria: 1.Current smoking 2.History of type 2 diabetes, coronary artery disease, peripheral vascular disease, or stroke 3. Uncontrolled hypertension 4.Musculoskeletal disorders limiting moderate-intensity exercise 5.Psychiatric or cognitive conditions that may compromise adherence 6.Clinically significant renal, hepatic, or hematologic disease. 7.Use of glucose-lowering agents, anti-inflammatory drugs, or dietary supplements known to influence vascular or metabolic function 8.Pregnancy or lactation

Design outcomes

Primary

MeasureTime frame
Blood pressure before and after 8 weeks of the intervention automatic oscillometric sphygmomanometer ,Arterial stiffness before and after 8 weeks of the intervention baPWV (BP-203RPE III, Omron Colin, Japan)

Secondary

MeasureTime frame
hs-CRP before and after 8 weeks of the intervention immunoturbidimetric assay,CBC-derived indices before and after 8 weeks of the intervention automated hematology analyzer ,Electrolytes before and after 8 weeks of the intervention ion-selective electrode method,Blood chemistry before and after 8 weeks of the intervention automated analyzer,Atherogenic indices before and after 8 weeks of the intervention calculation form lipid profiles,Anthropometry and Body Composition before and after 8 weeks of the intervention circumference and BIA-derived,Cardiorespiratory Fitness before and after 8 weeks of the intervention graded exercise test on cycle ergometer with breath-by-breath gas analysis,Muscular Endurance before and after 8 weeks of the intervention Push-up test and Wall sit test

Countries

Thailand

Contacts

Public ContactPiyaporn Tumnark

Faculty of Sports and Health Science, Kasetsart University

piyaporn.t@ku.th034355258

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026